Recent News

BriaCell Included in the List of Key Players in Immuno-Oncology – Genome Web Interviews BriaCell’s Head of R&D –

Berkeley, CA and Vancouver, BC – January 5, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of novel immuno-oncology therapeutics, today announced that Jason Napodano, senior equity analyst at BioNap Consulting, Inc., included BriaCell in the list of key players in immuno-oncology. […]